A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

NCT01187407 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1480

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder (MDD)

Interventions

DRUG: LY2216684
DRUG: Placebo
DRUG: SSRI

Sponsor

Eli Lilly and Company